PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
17396483-1	2007	Tositumomab/iodine-131 tositumomab (Bexxar) and ibritumomab tiuxetan (Zevalin) are radioimmunoconjugates targeting the CD20 antigen.	tositumomab I-131	36-42	keratin 20	Homo sapiens	119-123
21956491-12	2011	CONCLUSION: PARP inhibitors AZD-2281 and ABT-888 are highly radiosensitizing agents when used before external beam radiation and 131I-tositumomab.	tositumomab I-131	129-145	poly(ADP-ribose) polymerase 1	Homo sapiens	12-16
16979436-1	2006	Iodine-131 (I-131) tositumomab (Bexxar; GlaxoSmithKline, Research Triangle Park, NC) is one of two recently approved radiolabeled antibodies directed against the CD20 surface antigen found on normal B cells and in more than 95% of B cell non-Hodgkin"s lymphoma.	tositumomab I-131	32-38	keratin 20	Homo sapiens	162-166
16540013-6	2006	A similar anti-CD20 radiotherapeutic compound, 131I-tositumomab, was subsequently approved in the USA.	tositumomab I-131	47-63	keratin 20	Homo sapiens	15-19
11049969-0	2000	A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas.	tositumomab I-131	22-44	keratin 20	Homo sapiens	51-55
15023434-1	2004	Anti-CD20 antibodies radiolabeled with I-131 tositumomab (Bexxar) or Y-90-Ibritumomab tiuxetan (Zevalin), are similarly efficacious in treating chemotherapy-refractory non-Hodgkin"s lymphoma.	tositumomab I-131	58-64	keratin 20	Homo sapiens	5-9
12054068-1	2002	Bexxar (131I tositumomab) is a radiolabeled anti-CD20 monoclonal antibody for the treatment of relapsed and refractory follicular/low-grade and transformed non-Hodgkin"s lymphoma.	tositumomab I-131	0-6	keratin 20	Homo sapiens	49-53